潰瘍性大腸炎（UC）治療の世界市場-2023年～2030年

市場概要

潰瘍性大腸炎（UC）治療の世界市場は、2022年に69億米ドルに達し、2030年には111億米ドルに達し、有利な成長が予測されています。世界の潰瘍性大腸炎（UC）治療市場は、予測期間中（2023～2030年）に6.3%のCAGRを示すと予測されます。

潰瘍性大腸炎（UC）を含む炎症性腸疾患の増加、研究活動の活発化、製品承認数の増加、合併・買収・共同研究・製品導入などの市場開発などが、予測期間における潰瘍性大腸炎（UC）治療の世界市場の成長を促進すると予想される主な要因です。

市場力学

製品承認の増加が潰瘍性大腸炎（UC）治療市場の成長を促進

潰瘍性大腸炎（UC）の治療薬として承認された製品の増加は、予測期間における潰瘍性大腸炎（UC）治療市場の成長を後押しすると予想されます。例えば、2022年3月、製薬会社AbbVieは、1種類以上の腫瘍壊死因子（TNF）遮断薬で効果不十分または不耐容の中等度から極度の活動性の潰瘍性大腸炎（UC）の成人の治療薬として、RINVOQ（upadacitinib）の米国食品医薬品局（FDA）認可を取得しました。

同様に、2021年11月、欧州委員会はJyseleca（filgotinib）について、成人患者における活動性潰瘍性大腸炎（UC）の治療に対する効能・効果の追加を承認しました。

研究活動の増加が潰瘍性大腸炎（UC）治療の世界市場に成長機会をもたらすと期待される

研究活動の活発化は、世界市場に有望な成長機会をもたらしています。例えば、2021年3月、米国の製薬会社Eli Lilly and Companyはカナダで、活動性の潰瘍性大腸炎（UC）の成人患者を対象にLY3471851の有効性と安全性を評価する第II相臨床試験を開始しました。本試験の終了は2024年10月を予定しています。

厳しい規制当局の存在が予測期間中の潰瘍性大腸炎（UC）治療の世界市場を妨げると予測

潰瘍性大腸炎（UC）の新規開発薬の承認には厳しい規制機関が存在することが、予測期間中の世界市場の成長を阻害しています。例えば、潰瘍性大腸炎（UC）治療の承認と商業化を監督する主な規制機関には、米国食品医薬品局（USFDA）と欧州医薬品庁（EUの医薬品評価・監督機関）があります。

COVID-19影響分析

COVID-19のパンデミックと世界各国におけるロックダウンにより、あらゆる業種の企業の財務の健全性が影響を受けています。そのため、COVID-19公衆衛生緊急事態の期間中、米国食品医薬品局（FDA）は、スポンサーと研究者を支援し、試験参加者の安全を確保し、適正臨床実施基準（GCP）を遵守し、試験の完全性に対するリスクを最小限に抑えるための一般的な考慮事項を含むガイドラインを発表しました。

ロシア・ウクライナ紛争の影響分析

ロシア・ウクライナ紛争は、潰瘍性大腸炎（UC）の有病率が低く、この地域の主要な市場プレーヤーが不足していることから、世界の潰瘍性大腸炎（UC）治療市場に中程度の影響を及ぼすと考えられます。

ウクライナの診療所は、ロシア軍からの侵攻に耐え続けているもの、死者数の増加と限られた医療援助に追われています。あらゆる種類の医薬品が不足しています。ここでも基礎資材の輸出入の重要性が、予測期間中の潰瘍性大腸炎（UC）治療の世界市場の成長に若干の影響を与えると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 新興国市場の開発
    • 潰瘍性大腸炎（UC）の有病率の増加
  • 抑制要因
    • 厳しい規制
  • 機会
    • 研究活動の活発化
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 COVID-19分析

第7章 タイプ別

• 潰瘍性直腸炎
• 直腸S状結腸炎
• 左側大腸炎
• 膵炎または万能性大腸炎
• 劇症型大腸炎

第8章 薬剤別

• 免疫抑制剤
• 抗炎症薬
• 抗TNF生物製剤
• カルシニューリン阻害薬
• その他

第9章 投与経路別

• 経口
• 注射

第10章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • その他アジア太平洋地域
• 中東およびアフリカ
  • 主な地域別ダイナミクス

第12章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第13章 企業プロファイル

• Abbott Laboratories
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Ajinomoto
• AstraZeneca Plc.
• Eli-Lilly
• GlaxoSmithKline Plc.
• Index Pharmaceuticals Holdings AB
• Johnson & Johnson
• Merck & Co.
• Pfizer Inc.
• Sanofi

第14章 付録

Market Overview

The global ulcerative colitis treatment market reached US$ 6.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 11.1 billion by 2030. The global ulcerative colitis treatment market is expected to exhibit a CAGR of 6.3% during the forecast period (2023-2030).

The growing number of inflammatory bowel diseases including ulcerative colitis, increasing research activities, rising number of product approvals, and market developments such as mergers, acquisitions, collaborations, and product introductions are among the primary factors expected to drive the global ulcerative colitis treatment market growth in the forecast period.

Market Dynamics

Increasing Product Approvals Drive the Growth of the Ulcerative Colitis Treatment Market

The increasing product approvals for the treatment of ulcerative colitis are expected to boost the global ulcerative colitis treatment market growth in the forecast period. For instance, in March 2022, AbbVie, a pharmaceutical corporation obtained United States Food and Drug Administration (FDA) authorization for RINVOQ (upadacitinib) to treat adults with intermediate to extreme active ulcerative colitis (UC) who have had an insufficient response or intolerance to one or more tumor necrosis factor (TNF) blockers.

Likewise, in November 2021, the European Commission authorized an added indication for Jyseleca (filgotinib) to treat active ulcerative colitis in adult patients.

The Increase in Research Activities is Expected to Present the Global Ulcerative Colitis Treatment Market with Growth Opportunities

The increasing research activities are presenting the global market with prospective growth opportunities. For instnace, in March 2021, in Canada, Eli Lilly and Company, an American pharmaceutical company, began a phase II clinical investigation to evaluate the effectiveness and safety of LY3471851 in adult individuals with active ulcerative colitis (UC). The study is estimated to be concluded in October 2024.

The Presence of Stringent Regulatory Bodies is Estimated to Hamper The Global Ulcerative Colitis Treatment Market During the Forecast Period

The presence of stringent regulatory bodies for the approval of newly developed drugs for ulcerative colitis is hampering the global market growth in the forecast period. For instnace, the major regulatory bodies supervising the authorization and commercialization of ulcerative treatment drugs include the United States Food and Drug Administration (USFDA) and the European Medicines Agency, an agency of the European Union in charge of the evaluation and supervision of pharmaceutical products in European Union.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is thought to hold a moderate influence on the global ulcerative colitis treatment market, as there is a low prevalence of ulcerative colitis and a lack of primary market players in this region.

Though continuing to countenance invasions from Russian armies, Ukrainian clinics are forced by growing numbers of deaths and limited medical aid. There are shortages across all types of medications. Again, the significance of the import and export of fundamental materials are expected to have a slight impact on the global ulcerative colitis treatment market growth in the forecast period.

Segment Analysis

The global ulcerative colitis treatment market is segmented based on type, drug class, route of administration, distribution channel, and region.

The Immunosuppressant Drug Class is Estimated to Dominate the Global Ulcerative Colitis Treatment Market

Owing to the increasing positive outcomes from research investigation the immunosuppressant drug class segment is estimated to hold around 39.8% of the global market in the forecast period. For instance, in June AbbVie, a pharmaceutical corporation reported positive top-line outcomes from COMMAND, its Phase 3 maintenance investigation, revealing risankizumab (SKYRIZI, 180 mg or 360 mg subcutaneous [SC]) attained the preliminary endpoint of clinical remission (per Adapted Mayo Score) at week 52, and critical secondary endpoints in adult individuals with intermediate to extreme active ulcerative colitis.

Geographical Analysis

Europe is Estimated to Hold 28.6% of the Market Share Owing to the Growing Cases of Chronic Conditions in this Region

Owing to the increasing marketing applications acceptance and increasing research approval in Europe is estimated to boost the region's growth attaining 28% of the global market share by 2030. For instance, in December 2022, Pfizer Inc., an American multinational pharmaceutical corporation, reported that The European Medicines Agency (EMA) has received the Marketing Authorization Application (MAA) for etrasimod in the patient inhabitants with the conclusion expected in the first half of 2024.

Also, in August 2022, Abivax SA, a French clinical-stage, publicly traded biotechnology corporation concentrated on designing therapies that modulate the immune system for the treatment of chronic inflammatory conditions, viral diseases, and cancer obtained authorization from the central U.S. Institutional Review Board (IRB) for the protocols for the investigations allowing the beginning of registrations with obefazimod (ABX464) in UC in the U.S. A first-patient-in was expected for the end of the third quarter of this year.

Competitive Landscape

The major global players in the ulcerative colitis treatment market include: Abbott Laboratories, Ajinomoto, AstraZeneca Plc., Eli-Lilly, GlaxoSmithKline Plc., Index Pharmaceuticals Holdings AB, Johnson & Johnson, Merck & Co., Pfizer Inc., and Sanofi, among others.

Why Purchase the Report?

• To visualize the global ulcerative colitis treatment market segmentation based on type, drug class, route of administration distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of ulcerative colitis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Type mapping available in Excel consisting of key types of all the major players.

The global ulcerative colitis treatment market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Drug Class
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Market Developments
    • 4.1.1.2. Growing Prevalence of Ulcerative Colitis
  • 4.1.2. Restraints
    • 4.1.2.1. Stringent Regulatory Bodies
  • 4.1.3. Opportunity
    • 4.1.3.1. Increasing Research Activates
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Ulcerative Proctitis *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Proctosigmoiditis
• 7.4. Left-sided Colitis
• 7.5. Pancolitis or Universal Colitis
• 7.6. Fulminant Colitis

8. By Drug Class

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.1.2. Market Attractiveness Index, By Drug Class
• 8.2. Immunosuppressant*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Anti-Inflammatory Drugs
• 8.4. Anti-TNF biologics
• 8.5. Calcineurin Inhibitors
• 8.6. Others

9. By Route of Administration

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.1.2. Market Attractiveness Index, By Route of Administration
• 9.2. Oral*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Injectable

10. By Distribution Channel

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.1.2. Market Attractiveness Index, By Distribution Channel
• 10.2. Hospital Pharmacies *
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Retail Pharmacies
• 10.4. Online Pharmacies

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. The U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. The U.K.
    • 11.3.7.3. France
    • 11.3.7.4. Spain
    • 11.3.7.5. Italy
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan

Australia

• 11.5.7.4. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Abbott Laboratories *
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Ajinomoto
• 13.3. AstraZeneca Plc.
• 13.4. Eli-Lilly
• 13.5. GlaxoSmithKline Plc.
• 13.6. Index Pharmaceuticals Holdings AB
• 13.7. Johnson & Johnson
• 13.8. Merck & Co.
• 13.9. Pfizer Inc.
• 13.10. Sanofi

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us